Literature DB >> 19109800

Dangerous halo after neoadjuvant chemotherapy and two-step hepatectomy for colorectal liver metastases.

G Mentha1, S Terraz, P Morel, A Andres, E Giostra, A Roth, L Rubbia-Brandt, P Majno.   

Abstract

BACKGROUND: Bilobar colorectal metastases are a therapeutic challenge and require a multidisciplinary approach. The aim of this study was to describe the clinical and histological outcomes of patients having neoadjuvant chemotherapy and two-step hepatectomy with right portal vein occlusion for advanced bilateral colorectal metastases.
METHODS: A series of 23 consecutive patients treated with curative intent according to a standardized multidisciplinary management protocol was reviewed.
RESULTS: Of 23 patients, 22 completed the programme. There was no mortality and no Clavien grade III morbidity. Median survival from the start of treatment was 45 months, and 1-, 3- and 5-year Kaplan-Meier estimates were 95, 73 and 27 per cent respectively. On histology at the first operation, ten patients had a dangerous halo of proliferating tumour cells infiltrating the surrounding liver parenchyma, of variable importance (six focal and four diffuse), regardless of the response to chemotherapy of the metastases. The dangerous halo increased in prevalence and importance (six focal and seven diffuse) between the first and second operation.
CONCLUSION: Neoadjuvant chemotherapy followed by two-step hepatectomy with right portal vein occlusion is feasible, safe and may be advantageous to the patient. The appearance of a dangerous halo around the liver metastases may require adaptation of the surgical technique to decrease the risk of local recurrence. Copyright (c) 2008 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2009        PMID: 19109800     DOI: 10.1002/bjs.6436

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  28 in total

Review 1.  Parenchymal-sparing liver surgery in patients with colorectal carcinoma liver metastases.

Authors:  Fernando A Alvarez; Rodrigo Sanchez Claria; Sebastian Oggero; Eduardo de Santibañes
Journal:  World J Gastrointest Surg       Date:  2016-06-27

2.  Assessment of the residual tumour of colorectal liver metastases after chemotherapy: diffusion-weighted MR magnetic resonance imaging in the peripheral and entire tumour.

Authors:  Mathilde Wagner; Maxime Ronot; Sabrina Doblas; Céline Giraudeau; Bernard Van Beers; Jacques Belghiti; Valérie Paradis; Valérie Vilgrain
Journal:  Eur Radiol       Date:  2015-05-02       Impact factor: 5.315

3.  Significance of R1 Resection for Advanced Colorectal Liver Metastases in the Era of Modern Effective Chemotherapy.

Authors:  Christophe Laurent; Jean-Philippe Adam; Quentin Denost; Denis Smith; Jean Saric; Laurence Chiche
Journal:  World J Surg       Date:  2016-05       Impact factor: 3.352

4.  Pathological response grade of colorectal liver metastases treated with neoadjuvant chemotherapy.

Authors:  Gabriel Chan; Mazen Hassanain; Prosanto Chaudhury; Dionisios Vrochides; Amy Neville; Matthew Cesari; Petr Kavan; Victoria Marcus; Peter Metrakos
Journal:  HPB (Oxford)       Date:  2010-05       Impact factor: 3.647

5.  R1 Resection for Colorectal Liver Metastases: a Survey Questioning Surgeons about Its Incidence, Clinical Impact, and Management.

Authors:  Luca Viganò; Guido Costa; Matteo Maria Cimino; Fabio Procopio; Matteo Donadon; Daniele Del Fabbro; Jacques Belghiti; Norihiro Kokudo; Masatoshi Makuuchi; Jean-Nicolas Vauthey; Guido Torzilli
Journal:  J Gastrointest Surg       Date:  2018-06-08       Impact factor: 3.452

Review 6.  An Overview of the Current Management of Bilobar Colorectal Liver Metastases.

Authors:  Rebecca K L Griggs; Samir Pathak; Graeme Poston
Journal:  Indian J Surg Oncol       Date:  2017-08-09

7.  Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?

Authors:  Antoine Brouquet; Michael J Overman; Scott Kopetz; Dipen M Maru; Evelyne M Loyer; Andreas Andreou; Amanda Cooper; Steven A Curley; Christopher R Garrett; Eddie K Abdalla; Jean-Nicolas Vauthey
Journal:  Cancer       Date:  2011-03-28       Impact factor: 6.860

Review 8.  Breast cancer liver metastasis: current and future treatment approaches.

Authors:  Narmeen S Rashid; Jacqueline M Grible; Charles V Clevenger; J Chuck Harrell
Journal:  Clin Exp Metastasis       Date:  2021-03-06       Impact factor: 5.150

9.  Administration of anti-vascular endothelial growth factor antibody following hepatectomy does not inhibit remnant liver regeneration or growth of remnant metastases.

Authors:  Kazuhiko Kasuya; Minako Suzuki; Yuichi Nagakawa; Yoshiaki Suzuki; Satoru Kikuchi; Bunso Kyo; Takaaki Matsudo; Takao Itoi; Akihiko Tsuchida; Tatsuya Aoki
Journal:  Exp Ther Med       Date:  2011-12-06       Impact factor: 2.447

10.  The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus.

Authors:  René Adam; Aimery De Gramont; Joan Figueras; Ashley Guthrie; Norihiro Kokudo; Francis Kunstlinger; Evelyne Loyer; Graeme Poston; Philippe Rougier; Laura Rubbia-Brandt; Alberto Sobrero; Josep Tabernero; Catherine Teh; Eric Van Cutsem
Journal:  Oncologist       Date:  2012-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.